Stockscreener 앱 받기
0.368
6.36%
-0.025
시간 외 거래:
.38
0.012
+3.26%
Nexalin Technology Inc 주식(NXL)의 최신 뉴스
Nexalin Technology Inc (NXLIW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nexalin Technology Inc (NXL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nexalin Technology Inc (NXL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nexalin Technology Inc (NXL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nexalin Technology Inc (NXL) Institutional Confidence - TradingKey
Nexalin Technology Inc (NXL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nexalin Technology Inc (NXL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nexalin Technology Inc (NXL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nexalin Technology Inc (NXLIW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nexalin Technology Inc (NXLIW) Institutional Confidence - TradingKey
Nexalin Technology Inc (NXLIW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nexalin Technology Adopts Second Amended and Restated Bylaws Effective June 16, 2026 - Minichart
Nexalin Technology Inc (NXLIW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nexalin Overhauls Bylaws, Modernizes Corporate Governance Framework - TipRanks
Nexalin Technology (NXL) overhauls bylaws, lowers quorum and adds exclusive forum rules - Stock Titan
Nexalin abstracts accepted at NYC neuromodulation conference By Investing.com - Investing.com South Africa
Nexalin Technology Inc (NXL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nexalin Technology Inc (NXLIW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nexalin Technology Inc (NXLIW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nexalin Technology Inc (NXLIW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nexalin Technology Announces Acceptance of Two Clinical Abstracts for Presentation At 2026 Nyc Neuromodulation Conference - marketscreener.com
Nexalin abstracts accepted at NYC neuromodulation conference - Investing.com
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life - GlobeNewswire
Exclusive: Nexalin Brazil trial shows benefits across anxiety, sleep and quality of life - MSN
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Misses Amid Continued Development PhaseEarnings Outlook Update - newsline.com
Nexalin reports positive results from anxiety disorder trial By Investing.com - Investing.com Nigeria
NXL Should I Buy - Intellectia AI
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life - Sahm
Nexalin Technology, Inc. (NXL) stock price, news, quote and history - Yahoo Finance Australia
Nexalin Technology Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains 2%ROA Comparison - newsline.com
NXL Q1 2026 Earnings: EPS Misses Estimates, Stock Gains Despite Wider LossEarnings Surprise Score - newsline.com
Nexalin reports positive clinical trial results for anxiety and insomnia - grafa.com
Nexalin reports positive results from anxiety disorder trial - Investing.com UK
Nexalin Study Shows Strong Anxiety and Depression Response in Brazil Trial - Moomoo
Nexalin Technology, Inc. Reports Successful Clinical Trial Results for Non-Invasive Neurostimulation Treatment of Anxiety and Depression - Quiver Quantitative
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sale - 富途牛牛
Nexalin receives U.S. patent for neurostimulation method - Investing.com UK
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia - markets.businessinsider.com
Nexalin receives U.S. patent for neurostimulation method By Investing.com - Investing.com South Africa
Nexalin Technology Announces Issuance of U.S. Patent - GlobeNewswire
New brain stimulation patent targets anxiety, depression, insomnia - Stock Titan
Nexalin Technology | 8-K: Current report - Moomoo
Nexalin Acquires Digital Health Platform Ahead of FDA Pivotal Trial for Insomnia Treatment - Sleep Review
Nexalin Technology (NXL) Surges 16%: Breakout Potential Above ResistanceValue ETF - The Legal Advocate
Nexalin Technology earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Nexalin Technology earnings beat, revenue fell short of estimates - Investing.com
Nexalin Technology Q1 2026 Earnings: EPS Misses Estimates Amidst Narrowing LossesProfit Margin Analysis - The Legal Advocate
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Misses Estimates as Stock Surges on No Revenue - newsline.com
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Company Intensifies R&D SpendSegment Revenue Breakdown - newsline.com
Nexalin Technology, Inc.Common Stock (NQ: NXL - The Chronicle-Journal
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury - Sahm
Nexalin Technology (NXL) Surges 19% as Momentum Builds Toward Key ResistanceWave Equality - The Legal Advocate
Nexalin Technology (NXL) Q1 2026 Profit Slips to $-0.11 — Misses Analyst ForecastsFiscal Year Earnings - The Legal Advocate
House committee directs VA to research brain stimulation for TBI By Investing.com - Investing.com Australia
House committee directs VA to research brain stimulation for TBI - Investing.com
Maxim Group Maintains Nexalin Technology(NXL.US) With Buy Rating, Maintains Target Price $2 - Moomoo
Nexalin Technology Secures Key Neurostimulation Legislative - GlobeNewswire
0.93%
자본화:
|
볼륨(24시간):